AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28368672
Drug: Intensive arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive arm (idarubicin 9 mg/m2 daily for 3 days)
Trial: 28368672
Drug: Standard arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard arm (idarubicin 9 mg/m2 daily for 2 days)
Trial: 25381472
Drug: Ultrasound-guided corticosteroid
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided corticosteroid injection (40 mg/1 ml methylprednisolone acetate)
Trial: 25381472
Drug: Blinded corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded corticosteroid injection (40 mg/1 ml methylprednisolone acetate)
Trial: 17062303
Drug: IV pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV pantoprazole 160 mg/d for 3 days
Trial: 17062303
Drug: Omeprazole 160
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 160 mg/d for 3 days
Trial: 14597860
Drug: Orlistat 360
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 360 mg/day plus hypocaloric diet
Trial: 10954007
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (50 mg losartan daily and 10 mg enalapril daily)
Trial: 8598621
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of zileuton four times daily
Trial: 8598621
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of zileuton, 400 mg of zileuton, or placebo
Trial: 1421877
Drug: sham injections
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham injections (n = 13)
Trial: 27893064
Drug: Lower-protein group
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-protein group (1 g of bovine protein/100 mL of breast milk)
Trial: 27893064
Drug: Higher-protein group
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-protein group (1.8 g of bovine protein/100 mL of breast milk or individualized high-protein supplementation)
Trial: 24330475
Drug: LVD-ADV combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVD-ADV combination therapy
Trial: 24330475
Drug: ADV monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADV monotherapy
Trial: 21977923
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 300,000 IU of vitamin D3
Trial: 21977923
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vitamin D injection)
Trial: 17878495
Drug: Combined thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined thyroxine and triiodothyronine treatment
Trial: 2664509
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (325 mg every other day)
Trial: 19884558
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (BT) sleep intervention (Individualized Sleep Promotion Plan [ISPP])
Trial: 17438255
Drug: Gabapentin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (900 to 3600 mg/d for 8 weeks)
Trial: 16294457
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17beta‐estradiol/0.125 mg trimegestone
Trial: 16294457
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg 17beta‐estradiol/1 mg norethisterone acetate
Trial: 16294457
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17beta‐estradiol/0.5 mg norethisterone acetate
Trial: 12040347
Drug: Bivalirudin phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin phase A (1.0 mg/kg bolus, infusion of 2.5 mg/kg/h for 4 hours) plus abciximab
Trial: 12040347
Drug: Bivalirudin phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin phase B (0.5 mg/kg bolus, infusion of 1.75 mg/kg/h for the procedure duration) plus provisional abciximab
Trial: 12040347
Drug: Bivalirudin phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin phase C (0.75 mg/kg bolus, infusion of 1.75 mg/kg/h for the procedure duration) plus provisional abciximab
Trial: 12040347
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus planned abciximab
Trial: 9883403
Drug: Paracervical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracervical anesthesia (10 ml of 1.5 mepivacaine)
Trial: 8584295
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg four times a day for 4 weeks
Trial: 2122724
Drug: Sorbitol (70%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (70%, 0 to 60 mL daily for 4 weeks)
Trial: 27808556
Drug: Parent-Focused Therapy
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-Focused Therapy (PFT)
Trial: 15727575
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone for 2 weeks and intranasal budesonide for 12 months
Trial: 15727575
Drug: Endoscopic sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic sinus surgery and intranasal budesonide for 12 months
Trial: 7595708
Drug: Vinorelbine (NVB)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (NVB) 30 mg/m2 weekly
Trial: 7595708
Drug: Melphalan (ALK)
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan (ALK) 25 mg/m2 every 4 weeks
Trial: 2245951
Drug: morphine‐scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine‐scopolamine
Trial: 28857719
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate 10 mg
Trial: 28857719
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate 30 mg
Trial: 25180798
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate 50 mg
Trial: 25180798
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate 70 mg
Trial: 28857719
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (all doses combined)
Trial: 23610455
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment with radiotherapy
Trial: 21305536
Drug: High-dose omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose omeprazole (80-mg bolus followed by 8-mg/h infusion for 72 hours)
Trial: 21305536
Drug: Standard-dose omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose omeprazole (40-mg intravenous infusion once daily for 3 days)
Trial: 21305536
Drug: High-dose omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose omeprazole
Trial: 21305536
Drug: Standard-dose omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose omeprazole
Trial: 11793037
Drug: IL-2 receptor
RxNorm normalized name: Il-2 receptor alpha chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 receptor antagonists (basiliximab and daclizumab)
Trial: 9408981
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: single daily dose of netilmicin based upon weight, age and renal function (mean dose 298 +/- 29 mg, median 300 mg, range 250-350 mg)
Trial: 9408981
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: 150% of standard dose (mean 418 +/- 45 mg, median 400 mg, range 350-500 mg)
Trial: 9408981
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: 200% of standard dose (mean 525 +/- 41 mg, median 500 mg, range 400-550 mg)
Trial: 9408981
Drug: Group 4:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4: 250% of standard dose (mean 710 +/- 39 mg, median 650 mg, range 600-750 mg)
Trial: 8254242
Drug: Carotid endarterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotid endarterectomy added to best medical care including aspirin and control of manageable risk factors
Trial: 8254242
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical care including aspirin and control of manageable risk factors
Trial: 29354950
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with medication (once a day, five times per week, for 6 weeks, total 30 times)
Trial: 29354950
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maintained original treatment with antihypertensive medication)
Trial: 25257148
Drug: Extended-release quetiapine
RxNorm normalized name: quetiapine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release quetiapine (quetiapine XR; 150 or 300 mg/day)
Trial: 23713578
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment to lower blood pressure (target systolic level <140 mm Hg within 1 hour)
Trial: 23713578
Drug: Guideline-recommended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended treatment (target systolic level <180 mm Hg)
Trial: 23713578
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment to lower blood pressure
Trial: 21665546
Drug: recombinant LH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant LH (rLH) administration
Trial: 21665546
Drug: rLH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rLH administration
Trial: 11172114
Drug: Uterine balloon
RxNorm normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uterine balloon therapy
Trial: 24735024
Drug: Dignity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity therapy + standard palliative care (SPC)
Trial: 18172188
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen deprivation therapy (ADT) with goserelin 3.6 mg every 4 weeks and flutamide 250 mg tid for 2 months before and concurrent with external-beam radiotherapy (EBRT)
Trial: 18172188
Drug: Neoadjuvant androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant androgen deprivation therapy (ADT) with EBRT
Trial: 15567450
Drug: Armagnac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armagnac (30 ml/day for 2 weeks)
Trial: 15567450
Drug: Vodka (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vodka (same alcoholic strength, 30 ml/day for 2 weeks)
Trial: 11706098
Drug: Citicoline (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (1000 mg PO twice a day for 6 weeks)
Trial: 7961535
Drug: Fluoxetine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (up to 80 mg daily)
Trial: 7961535
Drug: Fluoxetine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (various doses: 20, 40, and 60 mg)
Trial: 7961535
Drug: Fluoxetine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (in responder extension)
Trial: 7961535
Drug: Fluoxetine (open-label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (open-label extension)
Trial: 28866091
Drug: Sodium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium intake measured by 24-hour urine collections (mean intake 3,903 mg/day, standard deviation 1037 mg/day)
Trial: 22412088
Drug: Brachial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brachial infusion of NO synthase inhibitor (N(G)-monomethyl-l-arginine [L-NMMA])
Trial: 22412088
Drug: Brachial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brachial infusion of cytochrome P450 epoxygenase inhibitor (fluconazole)
Trial: 22412088
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of L-NMMA and fluconazole
Trial: 20079863
Drug: Deferasirox 20
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox 20 mg/kg/day orally for 6 months
Trial: 11078227
Drug: Adenosine (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (140 microg/kg/min for 6 minutes) and Heparin (10,000 U bolus)
Trial: 30883671
Drug: 0.125% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% ropivacaine + 100 mcg of fentanyl
Trial: 30883671
Drug: 0.125% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% levobupivacaine + 100 mcg of fentanyl
Trial: 24671538
Drug: d-cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: d-cycloserine (DCS) 250 mg
Trial: 17160498
Drug: DFDBA/PRP combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFDBA/PRP combination
Trial: 15684017
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) combined with interstitial chemotherapy (carmustine) after microsurgery
Trial: 11991437
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg/day for 2 years
Trial: 9489270
Drug: Empirically Supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirically Supported Treatments (ESTs)
Trial: 9489270
Drug: Manualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized treatment
Trial: 7611583
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine intraarticularly diluted in 10 ml saline
Trial: 7611583
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg morphine intravenously diluted in 10 ml saline (control)
Trial: 76170
Drug: Aluminium hydroxide
RxNorm normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium hydroxide in large doses
Trial: 27736795
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of split-dose 4L polyethylene-glycol (group A)
Trial: 27736795
Drug: Split-dose sodium
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose sodium picosulphate/magnesium citrate (group B)
Trial: 27736795
Drug: Individualized preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized preparation based on a 3-item questionnaire (group C)
Trial: 27736795
Drug: Split-dose 4L
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose 4L polyethylene-glycol
Trial: 22232849
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg film-coated tablet (FCT)
Trial: 22232849
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg chewable tablet (CT)
Trial: 19188334
Drug: Midazolam (0.02‐0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.02‐0.1 mg/kg per hour)
Trial: 9314423
Drug: BNP infusion
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP infusion at a rate of 3.3 pmol x kg(‐1) x min(‐1) over 4 hours
Trial: 31791663
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination intravitreal anti-PDGFRβ 1 mg and aflibercept 2 mg (LD combo)
Trial: 31791663
Drug: High-dose combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose combination intravitreal anti-PDGFRβ 3 mg and aflibercept 2 mg (HD combo)
Trial: 31791663
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) alone
Trial: 26294293
Drug: Calcium (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1200 mg/day) and Vitamin D (800 IU/day)
Trial: 26294293
Drug: Calcium (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1200 mg/day), Vitamin D (800 IU/day), and Strontium ranelate (2 g daily)
Trial: 26200465
Drug: Physostigmine (0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (0.24 µg·kg·min)
Trial: 24135387
Drug: Impaired fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impaired fasting glucose (IFG) defined as 100-125 mg/dL
Trial: 21107327
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg per day, titrated to 100 mg per day for 13 months
Trial: 21107327
Drug: ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 5 mg per day, titrated to 10 mg per day for 13 months
Trial: 13677026
Drug: Fenspiride (Erespal)
RxNorm normalized name: fenspiride
DrugBank: Fenspiride (DB08979)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenspiride (Erespal) 80 mg per os 3 times a day for 10 days
Trial: 1492852
Drug: Loxiglumide 400
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide 400 mg
Trial: 1492852
Drug: Loxiglumide 800
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide 800 mg
Trial: 30775944
Drug: Diuretic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic therapy (DIUR-T)
Trial: 19143907
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sildenafil and doxazosin
Trial: 17314057
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) therapy, subcutaneous ingestion of 0.03-0.04 mg/kg once daily
Trial: 15134414
Drug: Theraflex-TMJ cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theraflex-TMJ cream
Trial: 9613278
Drug: Ketamine 10
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 10 mg (1 ml)
Trial: 3200265
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (1200 mg per day)
Trial: 3200265
Drug: Aspirin (1300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1300 mg per day)
Trial: 23472197
Drug: CDP323 100
RxNorm normalized name: CDP323
DrugBank: CDP323 (DB05092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP323 100 mg bid
Trial: 23472197
Drug: CDP323 500
RxNorm normalized name: CDP323
DrugBank: CDP323 (DB05092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP323 500 mg bid
Trial: 23472197
Drug: CDP323 1000
RxNorm normalized name: CDP323
DrugBank: CDP323 (DB05092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP323 1000 mg qd
Trial: 23472197
Drug: CDP323 1000
RxNorm normalized name: CDP323
DrugBank: CDP323 (DB05092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDP323 1000 mg bid
Trial: 14656749
Drug: Lipid administration
RxNorm normalized name: Lipid Administration Set 81"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid administration in ARDS patients
Trial: 14656749
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration in ARDS patients
Trial: 14656749
Drug: Lipid administration
RxNorm normalized name: Lipid Administration Set 81"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid administration in patients without ARDS